{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:18:07Z","timestamp":1785442687615,"version":"3.56.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"PDRadiopharma Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Cardiac amyloidosis requires quantitative assessment using technetium-99m pyrophosphate (\n                      <jats:sup>99m<\/jats:sup>\n                      Tc-PYP) single-photon emission computed tomography (SPECT)\/computed tomography (CT) for adequate discrimination and evaluation of disease extent. This study aimed to evaluate the utility of standardized uptake value (SUV) analysis using\n                      <jats:sup>99m<\/jats:sup>\n                      Tc-PYP SPECT\/CT in pathologically-confirmed transthyretin amyloid cardiomyopathy (ATTR-CM). The study also explored the relationship between local uptake heterogeneity and indicators of cardiac impairment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Forty patients diagnosed via heart biopsy and genetic analysis (20 ATTR-CM; 4 light-chain amyloidosis, 16 non-amyloidosis) were enrolled. The mean SUVs of the heart and aorta were measured using SPECT images. Discrimination performance was evaluated by comparing each SUV, the heart-to-aorta ratio (rSUV\n                      <jats:sub>H\/Ao<\/jats:sub>\n                      ), and the heart-to-contralateral-lung ratio with pathological findings serving as the gold standard. Polar maps were analyzed to assess local SUV distribution in patients with ATTR-CM. The coefficient of variation (COV) of myocardial uptake, difference score between the septum and lateral wall (%DS), base-to-apex variability, and total cardiac SUV were calculated and compared with echocardiographic parameters.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      All metrics were significantly different between the ATTR-CM and non-amyloidosis groups. The rSUV\n                      <jats:sub>H\/Ao<\/jats:sub>\n                      effectively differentiated patients with ATTR-CM from those with light-chain or non-amyloidosis. Local myocardial SUV distribution correlated with impaired cardiac function. Notably, COV showed significant correlations with e' (R\u2009=\u20090.782) and E\/e' (R\u2009=\u2009\u2009\u2212\u20090.625), linking heterogeneity to myocardial stiffness and diastolic dysfunction. Larger %DS, which predominantly reflected the\u00a0ATTR-CM pattern of high septal uptake, correlated significantly with thinner walls (average wall thickness, R\u2009=\u2009\u2009\u2212\u20090.655; relative wall thickness, R\u2009=\u2009\u2009\u2212\u20090.486). As the total cardiac SUV increased, the %DS decreased (reflecting more homogeneous distribution), and global longitudinal strain worsened (R\u2009=\u20090.614). These observations indicated that greater impairment was associated with a higher disease burden.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This study demonstrated that quantitative SPECT analysis provides a valuable tool for the diagnostic evaluation and differentiation of ATTR-CM. The rSUV\n                      <jats:sub>H\/Ao<\/jats:sub>\n                      offers high discriminatory performance. Local heterogeneity and total myocardial uptake are closely related to the disease burden and extent, as reflected by structural and functional abnormalities on echocardiography. These findings suggest potential relevance to the non-invasive assessment of these aspects of the disease at a single time point.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13550-025-01292-w","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T19:24:10Z","timestamp":1754076250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Differentiation and correlation of regional uptake heterogeneity with cardiac dysfunction in biopsy-proven transthyretin amyloid cardiomyopathy using quantitative single-photon emission computed tomography\/computed tomography: a single-center, cross-sectional study"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2980-5366","authenticated-orcid":false,"given":"Masakazu","family":"Tsujimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Tanahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Sarai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuki","family":"Asada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Izawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"1292_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","volume":"6","author":"S Bokhari","year":"2013","unstructured":"Bokhari S, Casta\u00f1o A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imag. 2013;6:195\u2013201. https:\/\/doi.org\/10.1161\/CIRCIMAGING.112.000132.","journal-title":"Circ Cardiovasc Imag"},{"key":"1292_CR2","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1016\/j.jacc.2020.04.022","volume":"75","author":"M Hanna","year":"2020","unstructured":"Hanna M, Ruberg FL, Maurer MS, Dispenzieri A, Dorbala S, Falk RH, et al. Cardiac scintigraphy with technetium-99m-labeled bone-seeking tracers for suspected amyloidosis: JACC review topic of the week. J Am Coll Cardiol. 2020;75:2851\u201362. https:\/\/doi.org\/10.1016\/j.jacc.2020.04.022.","journal-title":"J Am Coll Cardiol"},{"key":"1292_CR3","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.jcmg.2020.08.027","volume":"14","author":"TJ Poterucha","year":"2021","unstructured":"Poterucha TJ, Elias P, Bokhari S, Einstein AJ, DeLuca A, Kinkhabwala M, et al. Diagnosing transthyretin cardiac amyloidosis by technetium Tc 99m pyrophosphate: a test in evolution. JACC Cardiovasc Imag. 2021;14:1221\u201331. https:\/\/doi.org\/10.1016\/j.jcmg.2020.08.027.","journal-title":"JACC Cardiovasc Imag"},{"key":"1292_CR4","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.221082","volume":"306","author":"YM Khor","year":"2023","unstructured":"Khor YM, Cuddy SAM, Singh V, Falk RH, Di Carli MF, Dorbala S. 99mTc bone-avid tracer cardiac scintigraphy: role in noninvasive diagnosis of transthyretin cardiac amyloidosis. Radiology. 2023;306: e221082. https:\/\/doi.org\/10.1148\/radiol.221082.","journal-title":"Radiology"},{"key":"1292_CR5","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133:2404\u201312. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021612.","journal-title":"Circulation"},{"key":"1292_CR6","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","volume":"46","author":"E Perugini","year":"2005","unstructured":"Perugini E, Guidalotti PL, Salvi F, Cooke RMT, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46:1076\u201384. https:\/\/doi.org\/10.1016\/j.jacc.2005.05.073.","journal-title":"J Am Coll Cardiol"},{"key":"1292_CR7","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1253\/circj.CJ-20-0110","volume":"84","author":"H Kitaoka","year":"2020","unstructured":"Kitaoka H, Izumi C, Izumiya Y, Inomata T, Ueda M, Kubo T, et al. JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis. Circ J. 2020;84:1610\u201371. https:\/\/doi.org\/10.1253\/circj.CJ-20-0110.","journal-title":"Circ J"},{"key":"1292_CR8","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","volume":"26","author":"S Dorbala","year":"2019","unstructured":"Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2019;26:2065\u2013123. https:\/\/doi.org\/10.1007\/s12350-019-01760-6.","journal-title":"J Nucl Cardiol"},{"key":"1292_CR9","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1253\/circj.CJ-17-1111","volume":"82","author":"N Tsuda","year":"2018","unstructured":"Tsuda N, Shiraishi S, Oda S, Ogasawara K, Sakamoto F, Tomiguchi S, et al. Utility of single-photon emission computed tomography\/computed tomography fusion imaging with 99mTc-pyrophosphate scintigraphy in the assessment of cardiac transthyretin amyloidosis. Circ J. 2018;82:1970\u20131. https:\/\/doi.org\/10.1253\/circj.CJ-17-1111.","journal-title":"Circ J"},{"key":"1292_CR10","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1097\/MNM.0000000000001409","volume":"42","author":"M Tsujimoto","year":"2021","unstructured":"Tsujimoto M, Teramoto A, Dosho M, Tanahashi S, Fukushima A, Ota S, et al. Automated classification of increased uptake regions in bone single-photon emission computed tomography\/computed tomography images using three-dimensional deep convolutional neural network. Nucl Med Commun. 2021;42:877\u201383. https:\/\/doi.org\/10.1097\/MNM.0000000000001409.","journal-title":"Nucl Med Commun"},{"key":"1292_CR11","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.jcmg.2020.09.009","volume":"14","author":"KM Alexander","year":"2021","unstructured":"Alexander KM, Masri A. Recipe for success in transthyretin cardiomyopathy: monoclonal protein rule out, SPECT imaging, and genetic testing. JACC Cardiovasc Imaging. 2021;14:1232\u20134. https:\/\/doi.org\/10.1016\/j.jcmg.2020.09.009.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1292_CR12","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1097\/MNM.0000000000000854","volume":"39","author":"M Tsujimoto","year":"2018","unstructured":"Tsujimoto M, Shirakawa S, Teramoto A, Ishiguro M, Nakane K, Ida Y, et al. Fluctuation of quantitative values on acquisition time and the reconstruction conditions in 99mTc-SPECT. Nucl Med Commun. 2018;39:601\u20139. https:\/\/doi.org\/10.1097\/MNM.0000000000000854.","journal-title":"Nucl Med Commun"},{"key":"1292_CR13","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1007\/s12149-020-01485-4","volume":"34","author":"T Okui","year":"2020","unstructured":"Okui T, Kobayashi Y, Tsujimoto M, Satoh K, Toyama H, Matsuo K. Quantitative evaluation of anti-resorptive agent-related osteonecrosis of the jaw using bone single photon emission computed tomography in clinical settings: relationship between clinical stage and imaging. Ann Nucl Med. 2020;34:620\u20138. https:\/\/doi.org\/10.1007\/s12149-020-01485-4.","journal-title":"Ann Nucl Med"},{"key":"1292_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s12350-022-02988-5","volume":"30","author":"JC Avalon","year":"2023","unstructured":"Avalon JC, Fuqua J, Deskins S, Miller T, Conte J, Martin D, et al. Quantitative single photon emission computed tomography derived standardized uptake values on 99mTc-PYP scan in patients with suspected ATTR cardiac amyloidosis. J Nucl Cardiol. 2023;30:127\u201339. https:\/\/doi.org\/10.1007\/s12350-022-02988-5.","journal-title":"J Nucl Cardiol"},{"key":"1292_CR15","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s11604-022-01364-0","volume":"41","author":"N Matsuda","year":"2023","unstructured":"Matsuda N, Otsuka H, Otani T, Azane S, Kunikane Y, Otomi Y, et al. New quantitative indices of cardiac amyloidosis with 99mTc-pyrophosphate scintigraphy. Jpn J Radiol. 2023;41:428\u201336. https:\/\/doi.org\/10.1007\/s11604-022-01364-0.","journal-title":"Jpn J Radiol"},{"key":"1292_CR16","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1007\/s12350-021-02806-4","volume":"29","author":"G Roshankar","year":"2022","unstructured":"Roshankar G, White GC, Cadet S, Fine NM, Chan D, White JA, et al. Quantitative technetium pyrophosphate and cardiovascular magnetic resonance in patients with suspected cardiac amyloidosis. J Nucl Cardiol. 2022;29:2679\u201390. https:\/\/doi.org\/10.1007\/s12350-021-02806-4.","journal-title":"J Nucl Cardiol"},{"key":"1292_CR17","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1007\/s12350-021-02857-7","volume":"29","author":"S Watanabe","year":"2022","unstructured":"Watanabe S, Nakajima K, Wakabayashi H, Yoneyama H, Yoshida S, Komatsu J, et al. Volumetric evaluation of 99mTc-pyrophosphate SPECT\/CT for transthyretin cardiac amyloidosis: methodology and correlation with cardiac functional parameters. J Nucl Cardiol. 2022;29:3102\u201310. https:\/\/doi.org\/10.1007\/s12350-021-02857-7.","journal-title":"J Nucl Cardiol"},{"key":"1292_CR18","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.2967\/jnumed.124.267542","volume":"65","author":"RJH Miller","year":"2024","unstructured":"Miller RJH, Shanbhag A, Michalowska AM, Kavanagh P, Liang JX, Builoff V, et al. Deep learning-enabled quantification of 99mTc-pyrophosphate SPECT\/CT for cardiac amyloidosis. J Nucl Med. 2024;65:1144\u201350. https:\/\/doi.org\/10.2967\/jnumed.124.267542.","journal-title":"J Nucl Med"},{"key":"1292_CR19","first-page":"921","volume":"66","author":"S Tanahashi","year":"2021","unstructured":"Tanahashi S, Tsujimoto M, Kurose T, Uno M, Sarai M, Kawai H, et al. Examination of quantitative analysis method for cardiac amyloidosis by 99mTc-PYP scintigraphy. Jpn J Clin Radiol. 2021;66:921\u20138.","journal-title":"Jpn J Clin Radiol"},{"key":"1292_CR20","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/MNM.0000000000001680","volume":"44","author":"M Tsujimoto","year":"2023","unstructured":"Tsujimoto M, Fukushima A, Kawai H, Watanabe M, Tanahashi S, Sarai M, et al. Volume-based 18 f-fdg PET analysis of cardiac sarcoidosis using the descending aorta as a reference tissue. Nucl Med Commun. 2023;44:390\u20136. https:\/\/doi.org\/10.1097\/MNM.0000000000001680.","journal-title":"Nucl Med Commun"},{"key":"1292_CR21","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1093\/cvr\/cvac119","volume":"118","author":"A Porcari","year":"2023","unstructured":"Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. Cardiovasc Res. 2023;118:3517\u201335. https:\/\/doi.org\/10.1093\/cvr\/cvac119.","journal-title":"Cardiovasc Res"},{"key":"1292_CR22","doi-asserted-by":"publisher","first-page":"716","DOI":"10.2967\/jnumed.120.247312","volume":"62","author":"S Dorbala","year":"2021","unstructured":"Dorbala S, Park MA, Cuddy S, Singh V, Sullivan K, Kim S, et al. Absolute quantitation of cardiac 99mTc-pyrophosphate using cadmium zinc telluride-based SPECT\/CT. J Nucl Med. 2021;62:716\u201322. https:\/\/doi.org\/10.2967\/jnumed.120.247312.","journal-title":"J Nucl Med"},{"key":"1292_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcmg.2009.09.023","volume":"3","author":"IS Syed","year":"2010","unstructured":"Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imag. 2010;3:155\u201364. https:\/\/doi.org\/10.1016\/j.jcmg.2009.09.023.","journal-title":"JACC Cardiovasc Imag"},{"key":"1292_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12968-023-00952-x","volume":"25","author":"L Axel","year":"2023","unstructured":"Axel L. Modeling of factors affecting late gadolinium enhancement kinetics in MRI of cardiac amyloid. J Cardiovasc Magn Reson. 2023;25: 46. https:\/\/doi.org\/10.1186\/s12968-023-00952-x.","journal-title":"J Cardiovasc Magn Reson"},{"key":"1292_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12010094","volume":"12","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Pan R, Peng D, Dong Q, Zhu X. Pitfalls of the semi-quantitative analyzing 99mTc-pyrophosphate planar images for diagnosing transthyretin cardiac amyloidosis: a possible solution. Diagnostics. 2022;12: 94. https:\/\/doi.org\/10.3390\/diagnostics12010094.","journal-title":"Diagnostics"},{"issue":"8","key":"1292_CR26","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.2215\/CJN.08720811","volume":"7","author":"L Lobato","year":"2012","unstructured":"Lobato L, Rocha A. Transthyretin amyloidosis and the kidney. Clin J Am Soc Nephrol. 2012;7(8):1337\u201346. https:\/\/doi.org\/10.2215\/CJN.08720811.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1292_CR27","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jaccao.2024.03.004","volume":"6","author":"L Obici","year":"2024","unstructured":"Obici L, Mussinelli R, Palladini G. Learning from trials: time to look more closely at the kidneys in ATTR amyloidosis? JACC CardioOncol. 2024;6:307\u20139. https:\/\/doi.org\/10.1016\/j.jaccao.2024.03.004.","journal-title":"JACC CardioOncol"},{"key":"1292_CR28","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s10741-023-10332-3","volume":"28","author":"S Liang","year":"2023","unstructured":"Liang S, Liu Z, Li Q, He W, Huang H. Advance of echocardiography in cardiac amyloidosis. Heart Fail Rev. 2023;28:1345\u201356. https:\/\/doi.org\/10.1007\/s10741-023-10332-3.","journal-title":"Heart Fail Rev"},{"key":"1292_CR29","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jccase.2019.09.013","volume":"21","author":"Y Ochi","year":"2020","unstructured":"Ochi Y, Kubo T, Nakashima Y, Takahashi A, Baba Y, Hirota T, et al. A case report of an uncommon presentation of 99mtechnetium pyrophosphate scintigraphy in transthyretin cardiac amyloidosis: a potential diagnostic pitfall, pseudo-positive or pseudo-negative? J Cardiol Cases. 2020;21:50\u20133. https:\/\/doi.org\/10.1016\/j.jccase.2019.09.013.","journal-title":"J Cardiol Cases"},{"key":"1292_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.17996\/anc.23-00009","volume":"10","author":"H Suenaga","year":"2024","unstructured":"Suenaga H, Fukushima K, Ishii S, Hasegawa O, Muto Y, Yamakuni R, et al. Global and regional reduction of myocardial perfusion in patients with transthyretin type of cardiac amyloidosis: a dual SPECT study using 99mTc pyrophosphate and 201thallium. Ann Nucl Cardiol. 2024;10:16\u201322. https:\/\/doi.org\/10.17996\/anc.23-00009.","journal-title":"Ann Nucl Cardiol."},{"key":"1292_CR31","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s11604-021-01221-6","volume":"40","author":"K Ogasawara","year":"2022","unstructured":"Ogasawara K, Shiraishi S, Tsuda N, Sakamoto F, Oda S, Takashio S, et al. Usefulness of quantitative 99mTc-pyrophosphate SPECT\/CT for predicting the prognosis of patients with wild-type transthyretin cardiac amyloidosis. Jpn J Radiol. 2022;40:508\u201317. https:\/\/doi.org\/10.1007\/s11604-021-01221-6.","journal-title":"Jpn J Radiol"},{"key":"1292_CR32","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ijcard.2020.02.030","volume":"307","author":"C Grigoratos","year":"2020","unstructured":"Grigoratos C, Aimo A, Rapezzi C, Genovesi D, Barison A, Aquaro GD, et al. Diphosphonate single-photon emission computed tomography in cardiac transthyretin amyloidosis. Int J Cardiol. 2020;307:187\u201392. https:\/\/doi.org\/10.1016\/j.ijcard.2020.02.030.","journal-title":"Int J Cardiol"},{"key":"1292_CR33","doi-asserted-by":"publisher","DOI":"10.7326\/AITC202303210","volume":"176","author":"MW Bloom","year":"2023","unstructured":"Bloom MW, Gorevic PD. Cardiac amyloidosis. Ann Intern Med. 2023;176: ITC33\u201348. https:\/\/doi.org\/10.7326\/AITC202303210.","journal-title":"Ann Intern Med"},{"key":"1292_CR34","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jcmg.2015.05.014","volume":"9","author":"J Ternacle","year":"2016","unstructured":"Ternacle J, Bodez D, Guellich A, Audureau E, Rappeneau S, Lim P, et al. Causes and consequences of longitudinal LV dysfunction assessed by 2D strain echocardiography in cardiac amyloidosis. JACC Cardiovasc Imag. 2016;9:126\u201338. https:\/\/doi.org\/10.1016\/j.jcmg.2015.05.014.","journal-title":"JACC Cardiovasc Imag"},{"key":"1292_CR35","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1007\/s12350-023-03353-w","volume":"30","author":"S Watanabe","year":"2023","unstructured":"Watanabe S, Nakajima K, Toshima F, Wakabayashi H, Yoshida S, Yoneyama H, et al. Transthyretin amyloid cardiomyopathy disease burden quantified using 99mTc-pyrophosphate SPECT\/CT: volumetric parameters versus SUVmax ratio at 1 and 3 hours. J Nucl Cardiol. 2023;30:2721\u201335. https:\/\/doi.org\/10.1007\/s12350-023-03353-w.","journal-title":"J Nucl Cardiol"},{"key":"1292_CR36","doi-asserted-by":"publisher","first-page":"1146725","DOI":"10.3389\/fcvm.2023.1146725","volume":"10","author":"AG Caponetti","year":"2023","unstructured":"Caponetti AG, Accietto A, Saturi G, Ponziani A, Sguazzotti M, Massa P, et al. Screening approaches to cardiac amyloidosis in different clinical settings: current practice and future perspectives. Front Cardiovasc Med. 2023;10:1146725. https:\/\/doi.org\/10.3389\/fcvm.2023.1146725.","journal-title":"Front Cardiovasc Med"},{"key":"1292_CR37","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1007\/s00259-023-06408-9","volume":"51","author":"HSA Tingen","year":"2024","unstructured":"Tingen HSA, Tubben A, van\u2019t Oever JH, Pastoor EM, van Zon PPA, Nienhuis HLA, et al. Correction to: positron emission tomography in the diagnosis and follow-up of transthyretin amyloid cardiomyopathy patients: a systematic review. Eur J Nucl Med Mol Imaging. 2024;51:1798. https:\/\/doi.org\/10.1007\/s00259-023-06408-9.","journal-title":"Eur J Nucl Med Mol Imaging"}],"updated-by":[{"DOI":"10.1186\/s13550-026-01371-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000}}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01292-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-025-01292-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01292-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T17:46:23Z","timestamp":1776793583000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13550-025-01292-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1292"],"URL":"https:\/\/doi.org\/10.1186\/s13550-025-01292-w","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"9 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13550-026-01371-6","URL":"https:\/\/doi.org\/10.1186\/s13550-026-01371-6","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Fujita Health University Institutional Review Board (approval number: HM24-490). Given the retrospective nature of this research and the use of anonymized existing data, the Institutional Review Board waived the requirement for obtaining individual written informed consent. In lieu of written consent, an opt-out approach was implemented; information regarding the study was provided to potential participants through a publicly accessible disclosure document, allowing them the opportunity to decline participation. This opt-out procedure was also approved by the Institutional Review Board. All image data were anonymized prior to analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MT reports that financial support and article publishing charges were provided by PDRadiopharma Inc. The other authors declare that they have no known competing financial interests or personal relationships that influenced the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"97"}}